Scientist Home Future Health Ltd: A Plain-English Investor Guide

If you are considering investing in Scientist Home, here is the reality of their situation based on their 2025 financial results.

1. What do they actually do?

Scientist Home is a Hong Kong-based retailer of health supplements, such as their "Vein Cream," and basic health check-up services. The company acts as a middleman, purchasing its inventory from a private company owned by their CEO, Mr. Chan Siu Hung.

The company operates as a wellness brand rather than a clinical research firm. They do not own factories or medical patents, relying instead on customer service and retail distribution.

2. How are they performing?

While sales are growing, the company is spending money significantly faster than it earns it.

• Revenue: Sales reached $204,055 in 2025, a 69% increase from the $120,775 earned in 2024.
• Profitability: The company is operating at a loss. In 2025, the loss grew to $231,725, compared to a $14,980 loss in 2024.
• Efficiency: Expenses—including salaries, fees, and rent—jumped to $313,612 in 2025 from $66,065 in 2024. This 375% increase indicates that overhead costs are outpacing the growth of the customer base.

Currently, the company spends approximately $1.54 for every $1.00 of revenue it generates.

3. Financial Health: The "Going Concern" Warning

The company’s auditors have issued a "going concern" warning, which signals doubt regarding the company’s ability to remain in business over the next 12 months.

As of December 31, 2025, the company held $68,888 in cash. While they raised $354,000 through the sale of additional shares, they spent $248,000 on daily operations. Because their liabilities exceed their assets, the company faces a persistent cash shortage. Their survival is currently tied to their ability to raise further capital or reach profitability, both of which remain significant challenges.

4. Key Risks

• Insolvency Risk: The company cannot currently fund its own operations through sales. If they are unable to secure further investment, they risk running out of cash.
• Dependency on the CEO: Mr. Chan Siu Hung serves as the sole supplier, the top executive, and the primary shareholder. The business model is highly concentrated around his involvement and the existing supply agreement.
• Fixed Costs: The company is committed to long-term office and retail leases through 2028. These costs remain constant regardless of sales volume, which compounds the impact of their losses.
• Market Liquidity: Shares trade on the OTC market, where trading volume is thin. This can make it difficult to exit a position without negatively impacting the share price.

5. The Bottom Line

Scientist Home is a high-risk, early-stage company. While they are successfully growing their top-line revenue, their operational efficiency is declining. The company is currently in "survival mode," relying on the issuance of new shares to cover losses, which dilutes existing ownership. Given the "going concern" warning and the current cash burn rate, this remains a highly speculative investment.

Investor Tip: Before investing, compare the company's cash burn rate against their ability to generate new revenue. If the cost of operations continues to grow faster than sales, the company will likely need to return to the market for more capital, which may further impact your investment value.